NETO1

Across TCGA pan-cancer cohorts, NETO1 Mutation is linked to patient survival in 9 of 34 cancer types, making it a survival-associated NETO1 data layer compared with 23 for mass-spec protein and 1 for mass-spec protein.

The strongest signal is observed in adrenocortical carcinoma (ACC), where higher NETO1 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated NETO1 expression acts as an unfavorable survival marker, although some lineages such as UCEC and LUSC show a favorable association.

ACC, KIRP, and SARC are the cancer types where NETO1 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
ACC	DFS	Median	All	0.010	0.667	<.001	45	view →
KIRP	DFS	Median	All	0.040	0.912	<.001	36	view →
SARC	DFS	Median	All	0.086	0.611	<.001	12	view →
KIRC	DFS	Median	All	0.266	0.796	.020	6	view →
PRAD	DFS	Median	All	0.628	0.936	.005	6	view →
ESCA	DFS	Median	III,IV	0.205	0.457	.032	6	view →
UCEC	DFS	Median	All	0.966	0.890	.021	6	view →
LUSC	DFS	Median	All	0.639	0.377	.039	1	view →
COAD	OS	Median	II,III,IV	0.653	0.856	.031	1	view →

Pink = unfavorable, green = favorable. Showing the 9 strongest of 9 lineages.

NETO1–ACC (DFS)

Open the ACC breakdown →